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To the Editor: In an investigation of a pneumonic 
plague outbreak in Madagascar, Ramasindrazana et al. re-
ported isolation of Yersinia pestis from 2 patients and sero-
conversion in 2 additional patients; these data indicated 4 
(28.7%) of 14 diagnosed cases among described cases (1). 
The risk for overestimation of pneumonic plague contagion 
was illustrated by an outbreak in the Democratic Repub-
lic of the Congo that included cases of leptospirosis (2). 
In fact, thorough investigations in Uganda indicated that 2 
index patients transmitted Y. pestis to only 1 caregiver each 
and none to 23 additional untreated close contacts (3). An-
other investigation in China showed that 3 index patients 
exposed 214 contacts during 3–13 days; all contacts were 
quarantined, and no secondary cases were reported (4). 
Transmission of Y. pestis by respiratory droplets requires 
face-to-face exposure with a coughing patient, as can oc-
cur during funerals by close contact with coughing persons 
who may have been exposed to the pathogen while visiting 
or attending the patient before he or she died. Therefore, the 
threat for plague epidemics fueled by pneumonic plague 
can be reduced by measures such as isolating patients and 
wearing a mask when exposure is likely (5).
We propose the hypothesis that only the transmission 
of Y. pestis by ectoparasites, such as lice and fleas, by close 
contact with infected humans can sustain outbreaks and epi-
demics. In plague-endemic regions, to support the appropri-
ate management of patients and provide a rapid and accurate 
microbiological diagnosis, we recommend point of care lab-
oratories, some of which are now operating in a few remote 
regions of Africa. In addition to direct diagnosis of disease 
in humans, direct detection of Y. pestis at the point-of-care in 
potential sources and vectors would facilitate understanding 
of how plague epidemics sustain.
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To the Editor: The November 2017 issue of Emerg-
ing Infectious Diseases had 3 articles about leprosy, in-
cluding these topics: a United States–born patient who 
tested positive for Mycobacterium lepromatosis (1); a le-
thal case of Mycobacterium leprae manifested as Lucio’s 
phenomenon in Peru (2); and pointing out that leprosy is 
an emerging disease in the eastern United States, includ-
ing autochthonous cases without exposure to armadillos 
(3), which were previously shown to be a zoonotic source 
of transmission in the United States (4). Not only is lep-
rosy not disappearing in the United States and globally, 
but the signs are pointing to a more virulent mycobacte-
rial infection that is likely to be a microbial adaptation 
to the global use of multidrug therapy, as previously re-
ported (5). 
Lucio’s phenomenon is fortunately rare; there is no 
proven effective therapy for this type 3 reaction in leprosy 
patients. Historically, Lucio’s phenomenon was confined 
to Mexico, mostly in cases of diffuse lepromatous leprosy, 
also referred to as “Leprosy bonita.” In recent years, it has 
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been discovered elsewhere, including the first known case 
in India in 2001 (6). Two additional cases of lethal Lucio’s 
leprosy were reported in 2 immigrants from Singapore to 
the United States, who were shown to have M. leproma-
tosis and M. leprae (7). The report of Levis et al. is likely 
confirmed by the recent discovery of M. lepromatosis and 
Lucio’s outside of Mexico (5).
In summary, leprosy is an emerging infection in the 
United States, including autochthonous cases in the east-
ern United States. The reports in the November issue of 
Emerging Infectious Diseases of autochthonous M. lep-
romatosis and a lethal case of Lucio’s phenomenon out-
side Mexico are ominous signs of a more virulent form of 
emerging leprosy.
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